ArticlePloS one2019

Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms.

Guido España et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.